Medivir appoints Dr. Linda Basse as Chief Medical Officer
Stockholm, Sweden — Medivir AB (Nasdaq Stockholm: MVIR) announced today it has appointed Linda Basse as Chief Medical Officer effective October 1, 2018. Dr. Basse will report to CEO Christine Lind and join the Medivir Executive Team.
Dr. Basse has more than 18 years of drug development and medical marketing experience, including approvals and marketing of new cancer therapies. Her previous roles include Medical Director at Zealand Pharma with responsibility for an orphan disease drug candidate and Medical Director at Genmab with responsibilities leading to the approval of daratumumab and indication expansion of ofatumumab in hematology-oncology indications. She also held the position as Medical Director at Topotarget developing drugs for cancer, along with Medical Manager and Medical Advisor roles at Abbott Laboratories, Nycomed and NovoNordisk.
Dr. Basse holds an MD and PhD from Copenhagen University, and has done clinical research at Copenhagen University Hospital. She is also a member of the European Society of Medical Oncology and the American Society of Clinical Oncology.
“I am very excited to join Medivir with its broad portfolio of drug candidates with the potential to improve the lives of patients. I look forward to developing these drugs to market approvals for Medivir and in collaboration with its partners”, said Linda Basse.
“I am pleased to bring Linda’s expansive drug development and market experience to Medivir. With her strong track record, she will be a valuable member of the management team and responsible for both the clinical strategy and development of our pipeline”, said Christine Lind, CEO at Medivir.
For further information, please contact:
Christine Lind, CEO Medivir AB, phone: +46 (0)72 710 2205
Medivir AB is obliged to make this information public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact persons set out above, at 07.30 CET on September 10, 2018.
Medivir is a research-based pharmaceutical company with a focus on oncology. We have a leading competence within protease inhibitor design and nucleotide/nucleoside science and we are dedicated to developing innovative pharmaceuticals that meet great unmet medical needs. Medivir is listed on the Nasdaq Stockholm Mid Cap List (ticker: MVIR). www.medivir.com.